Treatment outcomes and clinical course of telomere-mediated MDS/AML. Swimmer plot of outcomes of 18 short telomere patients with MDS/AML clustered by co-occurrence of pulmonary fibrosis (PF). The age and treatment are shown to the right. Red bar shows time since diagnosis of MDS/AML, and purple indicates time since onset of pulmonary fibrosis symptoms. HSCT and lung transplant are graphically indicated along the timelines. The length of the bar represents follow-up through death or through last assessment. *This patient received standard acute lymphoblastic leukemia (ALL) therapy and therapy-related AML was diagnosed 8 months into the treatment, then he was treated with a mitoxantrone/etoposide salvage regimen. ***These 2 patients received standard intensive induction for high grade MDS and AML. ATG, antithymocyte globulin; Chemo, chemotherapy; CSA, cyclosporine; ESA, erythropoietin-stimulating agent; GCSF, granulocyte colony-stimulating factor; HMA, hypomethylating agent.